James Wilding

James Wilding

James joined Mathys and Squire in 2014.  James is experienced in EPO prosecution and also handles opposition and appeal work. He is also experienced in prosecuting SPC portfolios and regularly advises clients in this area.  He handles a range of life sciences technologies.

James Wilding


Year joined: 2014

Qualifications: MBiochem DPhil EPA CPA


James has managed the prosecution of significant European patent portfolios. He also handles EPO opposition and appeal work and has presented cases at inter partes and ex partes oral proceedings. James has also prosecuted SPC portfolios across Europe, regularly advises clients in this area and has experience in SPC contentious practice. He has worked with clients that include global pharmaceutical companies and universities. James has expertise in various areas of technology, including biochemistry, biotechnology, immunology, diagnostics, (oligo) nucleotide therapy, plant extracts and cardiac stents. He has prosecuted portfolios relating to therapeutic antibodies, bacterial vaccines and nucleic acid amplification techniques.


James has a master's degree in biochemistry and a doctorate on the biochemistry of heart disease, both from Oxford University. James also conducted post-doctoral research at Université Paris-XI on cardiac disease. He is an author of several peer-reviewed papers on this subject.

Membership & Organisations

James is a CIPA fellow and member of the EPI.

Follow us on twitter